Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Los Angeles, CaliforniaAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT07126665RecruitingPhase 1/Phase 2
Study of MHB088C plus MHB039A for advanced solid tumors
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This trial tests an experimental drug called rilvegostomig, given as a shot under the skin, for people with advanced solid tumors that have spread or can't be removed and have already had standard treatments. The study checks how the body processes the drug and its safety.
Huntersville, North CarolinaAges 18 years+ - NCT07656116RecruitingPhase 1
Oncolytic virus therapy for advanced solid tumors
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Langfang, HebeiAges 18 years+ - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT06038396RecruitingPhase 1/Phase 2
A study of RC118 plus toripalimab/RC148 for advanced stomach cancer
This trial tests a new drug combination (RC118 plus toripalimab/RC148) for people with advanced stomach or gastroesophageal junction cancer. It’s for those whose cancer has not responded to standard treatment and whose tumors have a specific protein called Claudin 18.2.
Fuzhou, FujianAges 18–75 - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75 - NCT07444775RecruitingPhase 3
Comparing two types of radiation for large tumors
This phase 3 trial tests a newer radiation technique called Lattice Radiation Therapy against standard radiation for people with large solid tumors (over 5 cm) that cannot be removed by surgery or treated with standard radiation. The goal is to see if the newer approach provides better pain relief and tumor control.
Toronto, OntarioAges 18–99 - NCT06443489RecruitingPhase 1
SHR-4849 for advanced solid tumors
This trial tests a new drug called SHR-4849 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have limited choices.
Jilin City, ChangchunAges 18–75 - NCT05857332RecruitingPhase 1
Testing a new drug for CLDN18.2-positive solid tumors
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06877650RecruitingPhase 1/Phase 2
Study of JMT108 for advanced solid tumors
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06882135RecruitingPhase 1
Testing an experimental drug for advanced solid tumors
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06349408RecruitingPhase 1
Testing IBI3001 for advanced solid tumors
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
Wollongong, New South WalesAges 18 years+ - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06187402RecruitingPhase 1/Phase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06928922RecruitingEarly Phase 1
Inhaled mRNA vaccine for advanced lung cancer and lung metastases
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
BeijingAges Up to 99 years - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.